Related Experiment Video
Updated: Sep 18, 2025
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Carvedilol is associated with lower mortality than other nonselective beta-blockers in patients with cirrhosis
Michael J Mullarkey1, Gerald O Ogola2, Sumeet K Asrani3
1Department of Gastroenterology, Baylor Scott & White Medical Center, Temple, Texas, USA.
Insights
Carvedilol is more effective than nadolol or propranolol for treating cirrhosis patients with portal hypertension. This real-world study shows carvedilol reduces hepatic decompensation and mortality risk.
Area of Science:
- Hepatology
- Clinical Pharmacology
- Internal Medicine
Background:
- Recent guidelines suggest carvedilol as first-line for cirrhosis with portal hypertension.
- Existing recommendations lack real-world, head-to-head comparative data.
- Previous data relied on impractical surrogate markers like hepatic venous pressure gradients.
Purpose of the Study:
- To compare the effectiveness of carvedilol versus other nonselective beta-blockers in real-world cirrhosis patients.
- To evaluate the impact of carvedilol on hepatic decompensation and mortality.
- To provide evidence supporting clinical guidelines for portal hypertension management.
Main Methods:
- Retrospective case-control study of patients with cirrhosis and portal hypertension.
- Comparison of carvedilol versus nadolol or propranolol treatment groups.
- Propensity score matching and time-dependent Cox regression used for risk adjustment.
Main Results:
- Carvedilol use was associated with a significantly lower hazard of hepatic decompensation (P < 0.001).
- Patients on carvedilol demonstrated a reduced hazard of all-cause mortality (P = 0.03).
- Carvedilol's benefits extended to reduced risks of ascites, encephalopathy, and variceal bleeding.
Conclusions:
- Findings support carvedilol for patients with cirrhosis and portal hypertension.
- Carvedilol use is linked to decreased hepatic decompensation and improved survival.
- This study provides real-world evidence for carvedilol's efficacy in managing portal hypertension complications.
Background:
Recent guidelines have suggested that carvedilol should be first-line treatment in patients with cirrhosis and portal hypertension. This recommendation is based on data that rely on clinically impractical surrogates such as hepatic venous pressure gradient measurements. There is limited head-to-head data comparing carvedilol to other nonselective beta-blockers in the real-world setting.
Methods:
This retrospective case-control study from a large health system compared patients with cirrhosis determined by ICD-10 algorithm and platelet count <150, who were treated with carvedilol versus nadolol or propranolol. Outcomes including hepatic decompensation (ascites, encephalopathy, variceal bleeding) and all-cause mortality were analyzed with adjustment for potential confounding using propensity score matching and time-dependent Cox regression.
Results:
Among the 2302 cirrhosis patients meeting inclusion criteria, 1629 (70.8%) were on carvedilol and 673 (29.2%) were on nadolol or propranolol. In risk-adjusted analysis, patients on carvedilol had a lower hazard of hepatic decompensation (P < 0.001) and lower hazard of mortality (P = 0.03) compared to patients on propranolol/nadolol. The superiority of carvedilol applied equally to each decompensation type: ascites, encephalopathy, and variceal bleeding.
Conclusion:
These findings support the use of carvedilol in patients with cirrhosis and clinically apparent portal hypertension, to decrease the risk of hepatic decompensation and improve survival.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:28Antihypertensive Drugs: Types of β-Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System